Alzheimer’s And Surrogate Endpoints: FDA’s On A Case-By-Case Basis Per New Guidance

 
• By Sarah Karlin-Smith
  
Alzheimer disease as a neuropathology memory loss due to brain degeneration and decline as a surreal medical neurology illness concept.
• Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA

More from Agency Leadership